22 Breast Cancer Clinical Trials in Aurora, IL (2026)

Q: How do I join a clinical trial in Aurora?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you.

Recruiting Breast Cancer Studies in Aurora

NCT03053193Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing ...

Aurora, IL30,000 participantsAgendia

View Study Details

NCT01042379Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learn...

Aurora, ILPHASE25,000 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06401421Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for cir...

Aurora, IL1,800 participantsExact Sciences Corporation

View Study Details

NCT06312176Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone rece...

Aurora, ILPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07085767Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for...

Aurora, ILPHASE31,000 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT01503190Recruiting

The Immune System's Response to Young Women's Breast Cancer

This study plans to learn more about the immune system's response to breast cancer in young women....

Aurora, IL800 participantsUniversity of Colorado, Denver

View Study Details

NCT06380751Recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...

Aurora, ILPHASE3788 participantsAstraZeneca

View Study Details

NCT01185132Recruiting

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effe...

Aurora, ILPHASE3660 participantsRocky Mountain Cancer Centers

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

Aurora, ILPHASE3625 participantsAstraZeneca

View Study Details

NCT06926868Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physi...

Aurora, ILPHASE2600 participantsBristol-Myers Squibb

View Study Details

NCT06435429Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the...

Aurora, ILPHASE3550 participantsJazz Pharmaceuticals

View Study Details

NCT06377852Recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effec...

Aurora, ILPHASE3500 participantsAmerican Society of Clinical Oncology

View Study Details

NCT06230185Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR...

Aurora, IL422 participantsPersonalis Inc.

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

Aurora, ILPHASE1383 participantsIambic Therapeutics, Inc

View Study Details

NCT06369285Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-n...

Aurora, ILPHASE2225 participantsPuma Biotechnology, Inc.

View Study Details

NCT05508906Recruiting

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis ...

Aurora, ILPHASE1190 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06764940Recruiting

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastas...

Aurora, ILPHASE2120 participantsBiostar Pharma, Inc.

View Study Details

NCT03606967Recruiting

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with tripl...

Aurora, ILPHASE286 participantsNational Cancer Institute (NCI)

View Study Details

NCT06686394Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cance...

Aurora, ILPHASE181 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06813053Recruiting

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

This is a study to assess the feasibility and acceptability of a novel decision aid (DA) in a newly diagnosed, early-stage breast cancer population. Insights gained from patient feedback and the imple...

Aurora, ILNA60 participantsUniversity of Colorado, Denver

View Study Details

NCT06908928Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-...

Aurora, ILPHASE152 participantsMabwell (Shanghai) Bioscience Co., Ltd.

View Study Details

NCT06430541Recruiting

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main questi...

Aurora, ILPHASE120 participantsUniversity of Colorado, Denver

View Study Details

About Breast Cancer Clinical Trials in Aurora

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 22 breast cancer clinical trials recruiting participants in Aurora, IL. These studies are seeking a combined 45,162 participants. Research is being sponsored by Agendia, QuantumLeap Healthcare Collaborative, Exact Sciences Corporation and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Aurora — FAQ

Are there breast cancer clinical trials in Aurora?

Yes, there are 22 breast cancer clinical trials currently recruiting in Aurora, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 22 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated August 29, 2026 from ClinicalTrials.gov